tirzepatide for menopause New research from a Mayo Clinic–led study suggests that postmenopausal women using hormone therapy may experience greater weight loss when treated with tirzepatide, a GLP-1–based medication overweight and obesity. In Mayo Clinic Study: Menopausal Hormone

KEY OBSERVATIONS Cold-chain packaging was solid

Most NAION cases reported in clinical studies occurred within the first year of semaglutide use, suggesting a drug-induced effect related to treatment initiation or rapid metabolic changes

Nausea can occur but is easily treated

According to data released by the FDA, common Mounjaro side effects include: 1 Nausea Vomiting Diarrhea Constipation Abdominal pain In more severe cases, patients may experience: Kidney damage Diabetic retinopathy Pancreatitis Severe gastrointestinal reactions Acute gallbladder disease Mounjaro has also caused thyroid abnormalities and led to an increased risk of several cancers in animal trials and may cause tumor formation in humans